Why Novartis Remains A 'Buy' After Beating Expectations Again
Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...
pharmaphorum2d
Novartis’ COPD combo show benefits in switching from established drugs
such as inhaled steroid-containing combination therapies," said Vasant Narasimhan, Global Head Drug Development and Chief Medical Officer for Novartis. "By showing that improved symptom control ...
pharmaphorum3d
Novartis raises mid-term sales outlook on pipeline promise
said chief executive Vas Narasimhan. The event comes just over a year after Novartis completed the dismantling of its diversified life sciences model with the spinout of generic and biosimilar ...
Novartis3d
Parental leave – A leadership opportunity
At Novartis, we believe in the importance of balancing professional and personal responsibilities. This belief is embodied through our inclusive parental leave policy, which supports all our people in ...
Novartis3d
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
said David Soergel, M.D., Global Head, Cardiovascular, Renal and Metabolism Development Unit, Novartis. “Building on our longstanding expertise in nephrology and recent advancements in kidney diseases ...
Yahoo Finance3d
Novartis AG (NVS)
After hours: February 28 at 7:55:42 p.m. EST ...
ThePrint5d
S.L. Narasimhan
Lt. Gen. (Retd) S.L. Narasimhan is member, National Security Advisory Board, and Distinguished Fellow, Centre for Air Power Studies. His areas of expertise are China, strategy, international relations ...